What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 1, Pre-Registered Trial).

What question did this study set out to answer?

This trial aimed to evaluate the efficacy of huCART19 in high-risk relapsed/refractory B-ALL patients.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

This trial aimed to evaluate the efficacy of huCART19 in high-risk relapsed/refractory B-ALL patients.
Phase II clinical trial conducted on patients aged 0-29 with high-risk r/r B-ALL.
Patients received huCART19 after lymphodepletion with fludarabine and cyclophosphamide.
Outcomes measured included event-free survival (EFS), overall response rate (ORR), and minimal residual disease (MRD) assessments.
94% of patients were in complete remission or incomplete hematologic recovery by day 28.
EFS at 2 years was 65%, and overall survival at 2 years was 74%.
Adverse events included CRS in 90% of CAR-naïve patients, demonstrating manageable toxicity.

No takes yet. Share an insight, caveat, or question.

Phase II clinical trial of huCART19 improved outcomes in high-risk B-ALL, suggesting effective salvage therapy strategies for relapses.

Li et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark